Skip to content

Concentra Group

US · CON #2185 by market cap Listed 2024
36.40 0.00 0.00%
Live - 5344 symbols - heartbeat 130s ago · 2026-10-07 19:54
After-hours 36.40 0.00%
Market cap
4.64B
P/B
9.73
EPS
1.30
Reader sentiment Are you bullish or bearish on CON?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Above fair value
18.61 fair value ≈ 22.68 26.75
  • Implied fair-value range of 18.61-26.75, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +60.5% above the average-multiple fair value of 22.68.

Valuation each multiple against its own 5-year range

P/B ratio 9.73 Expensive vs history 88th percentile
5-year average 7.64 · #37 of 40 in Medical Care Facilities
P/E ratio 23.48 Expensive vs history 100th percentile
5-year average 17.45 · forward 20.75 · #18 of 30 in Medical Care Facilities
P/S ratio 2.03 Expensive vs history 100th percentile
5-year average 1.45 · forward 1.92 · #43 of 50 in Medical Care Facilities

Vs. peers Medical Care Facilities

Company Market cap P/E (TTM) P/B Div yield
Concentra Group (CON) 4.64B 23.48 9.73 0.69%
HCA Healthcare (HCA) 95.08B 14.73 -14.32 0.68%
Tenet Healthcare (THC) 20.92B 10.04 4.49 0.00%
Encompass Health (EHC) 12.08B 19.95 4.65 0.62%
DaVita (DVA) 11.28B 14.57 -14.74 0.00%
Fresenius Medical Care (FMS) 11.01B 11.14 0.78 4.13%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value34.22 Economic moatNarrow UncertaintyMedium

Trading 6.0% above Morningstar's fair value estimate.

Fair value

Concentra Group Holdings Parent Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $34.22 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.

The firm's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 10.5% lies in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

Conversely, the firm's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's assets turnover ratio of 0.8, a core component of profitability, ranks in the top 40% globally. This exemplifies its robust ability to scale the benefits it wrings out of a fixed set of assets and inventory. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.